Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 40 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
70 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Biosynex Pharma Benelux from Sint-Joost-ten-Node, company number BE0787324947, closed financial year 2025 with a result of € -678,477 after tax. For that financial year Biosynex Pharma Benelux recorded a gross margin of € 259,103 and equity of € 1.7 million. Compared with financial year 2024, the result moved from € -714,864 to € -678,477. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 22, 2026.
€ 1.7 million
▼ 29% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -678,477
▲ 5 % less loss than in 2024
Profit after tax over the fiscal year.
€ 65,498
▼ 61% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.8 million.
People and assets in 2025
7.2
▲ 0.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 548,455
▲ 5% vs 2024
€ 76,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 19
▼ 90% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1.2 million
▲ 23% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 78,957
▼ 31% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 11,163 | € 1,402,154 | - | - | |
| Gross margin | € 644,860 | € 70,109 | € 211,995 | € 259,103 | ▲ 22% |
| Profit after taxes | € 356,266 | € -764,493 | € -714,864 | € -678,477 | ▲ € 36,388 |
| Equity | € 3,856,266 | € 3,091,459 | € 2,376,594 | € 1,698,117 | ▼ 29% |
| Total debts | € 3,280,597 | € 553,400 | € 1,054,472 | € 1,237,698 | ▲ 17% |
| Cash | € 3,499,418 | € 43,358 | € 166,147 | € 65,498 | ▼ 61% |
| Retained profit | € 356,266 | € -408,541 | € -1,123,406 | € -1,801,883 | ▼ € 678,477 |
| Balance sheet total | € 7,136,863 | € 3,644,858 | € 3,431,066 | € 2,935,815 | ▼ 14% |
| Employees (FTE) | 0 | 6 | 6.5 | 7.2 | ▲ 0.7 |
Key figures of Biosynex Pharma Benelux, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Biosynex Pharma Benelux?
What happened at Biosynex Pharma Benelux in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 678,477. Source: NBB ↗
- New establishment in Wavre. KBO
- New establishment in Sint-Joost-ten-Node. KBO
- Start of the company according to the CBE. KBO
- Biosynex SA became a director. NBB
In short
From € 356,266 profit in 2022 to € 678,477 loss in 2025.
Paid € 135,223 in corporate taxes since 2022.
Best year ever: 2022, with € 356,266 profit.
On average € 36,000 of value added per employee in 2025.
A new publication or filing at Biosynex Pharma Benelux? We notify you, reason included.
Follow Biosynex Pharma BeneluxDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Biosynex Pharma Benelux is Biosynex SA.
Directors
According to the 2025 annual accounts
Director · represented by Larry Abensur
since 2022
Establishments
Establishment units
Physical locations of this company
Bolwerklaan 21 box b8
1210 Sint-Joost-ten-Node
Avenue Sabin 14
1300 Wavre
Active since 10 October 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 70 companies are registered at this address.
All companies at this address →DEUTSCH-BELGISCH-LUXEMBURGISCHE HANDELSKAMER - BELGISCH-LUXEMBURGS-DUITSE KAMER VAN KOOPHANDEL - CHAMBRE DE COMMERCE BELGO-LUXEMBOURGEOISE-ALLEMANDE
€ 1.8 million revenue · 2025
MENSURA Service Externe de Prévention et de Protection au travail
€ 128.3 million revenue · 2025
PensioPlus (nederlands)
€ 848,627 gross margin · 2025
GROUPE GM BENELUX
€ 479,759 gross margin · 2025
CWT BELGIUM
€ 7.3 million revenue · 2025
+65 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0787.324.947
- VAT number
- BE 0787.324.947
- Registered office
- Bolwerklaan 21 bus b8, 1210 Sint-Joost-ten-Node
- Names & denominations
- Biosynex Pharma Benelux
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 June 2022
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering